In fact, nSMase2 gene ablation or pharmacological inhibition of nSMase2 activity markedly reduces age-enhanced inflammation in health10, the higher propensity for atherosclerotic lesions in the ApoE−/− mouse17 and, more significantly for CKD, the release of exosomes initiating medial calcification16. Here, SMPD3 is linked to chronic kidney disease.